Brendan J Nolan1,2, Jane Sorbello1, Nigel Brown3, Goce Dimeski2,3, Warrick J Inder4,5. 1. Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia. 2. Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. 3. Department of Chemical Pathology, Pathology Queensland, Brisbane, QLD, Australia. 4. Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia. warrick.inder@health.qld.gov.au. 5. Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. warrick.inder@health.qld.gov.au.
Abstract
PURPOSE: The ACTH1-24 stimulation test is commonly used to assess the hypothalamic-pituitary-adrenal (HPA) axis. Given variations in CBG concentration and binding affinity, serum total cortisol may misclassify some patients. Salivary cortisol correlates well with serum free cortisol but is easier to measure and widely available in commercial laboratories. The aim of this study was to investigate the utility of measuring salivary cortisol during the ACTH1-24 stimulation test. DESIGN AND METHODS: Case-control study in a clinical research facility. Eighty-seven patients with suspected cortisol deficiency, twenty-four healthy controls, and ten healthy women on the oral contraceptive (OC) underwent an intravenous 250 µg ACTH1-24 stimulation test. Concordance of ACTH1-24 stimulated serum and salivary cortisol was evaluated. RESULTS: There was a significant difference in serum cortisol between the healthy volunteers and the women on the OC (P < 0.001) but no difference in salivary cortisol. The lower limit of the reference interval for salivary cortisol at 60 min was 26 nmol/L. 27/89 (30%) of tests with suspected HPA axis disorder failed the 60 min serum cortisol cut-off of 500 nmol/L. Of these, 24/27 (89%) had a salivary cortisol of <26 nmol/L. In contrast, 12/19 (63%) tests and 5/43 (12%) tests where the 60 min serum cortisol was 500-599 and ≥600 nmol/L, respectively had a salivary cortisol of <26 nmol/L. CONCLUSIONS: Salivary cortisol provides additional diagnostic value during the 250 µg ACTH1-24 stimulation test in patients with proven or suspected alterations in CBG and potentially those with a borderline 60 min serum cortisol 500-599 nmol/L.
PURPOSE: The ACTH1-24 stimulation test is commonly used to assess the hypothalamic-pituitary-adrenal (HPA) axis. Given variations in CBG concentration and binding affinity, serum total cortisol may misclassify some patients. Salivary cortisol correlates well with serum free cortisol but is easier to measure and widely available in commercial laboratories. The aim of this study was to investigate the utility of measuring salivary cortisol during the ACTH1-24 stimulation test. DESIGN AND METHODS: Case-control study in a clinical research facility. Eighty-seven patients with suspected cortisol deficiency, twenty-four healthy controls, and ten healthy women on the oral contraceptive (OC) underwent an intravenous 250 µg ACTH1-24 stimulation test. Concordance of ACTH1-24 stimulated serum and salivary cortisol was evaluated. RESULTS: There was a significant difference in serum cortisol between the healthy volunteers and the women on the OC (P < 0.001) but no difference in salivary cortisol. The lower limit of the reference interval for salivary cortisol at 60 min was 26 nmol/L. 27/89 (30%) of tests with suspected HPA axis disorder failed the 60 min serum cortisol cut-off of 500 nmol/L. Of these, 24/27 (89%) had a salivary cortisol of <26 nmol/L. In contrast, 12/19 (63%) tests and 5/43 (12%) tests where the 60 min serum cortisol was 500-599 and ≥600 nmol/L, respectively had a salivary cortisol of <26 nmol/L. CONCLUSIONS: Salivary cortisol provides additional diagnostic value during the 250 µg ACTH1-24 stimulation test in patients with proven or suspected alterations in CBG and potentially those with a borderline 60 min serum cortisol 500-599 nmol/L.
Authors: Michael P Cornes; Helen L Ashby; Yasmeen Khalid; Harit N Buch; Clare Ford; Rousseau Gama Journal: Ann Clin Biochem Date: 2015-02-27 Impact factor: 2.057
Authors: Rasa Kazlauskaite; Arthur T Evans; Carmen V Villabona; Tariq A M Abdu; Bruno Ambrosi; A Brew Atkinson; Cheung Hei Choi; Richard N Clayton; C Hamish Courtney; E Nazli Gonc; Mohamad Maghnie; Susan R Rose; Steven G Soule; Karen Tordjman Journal: J Clin Endocrinol Metab Date: 2008-08-12 Impact factor: 5.958
Authors: Ilias Perogamvros; Laura J Owen; Brian G Keevil; Georg Brabant; Peter J Trainer Journal: Clin Endocrinol (Oxf) Date: 2009-03-19 Impact factor: 3.478
Authors: Yoon Ji Kim; Jung Hee Kim; A Ram Hong; Kyeong Seon Park; Sang Wan Kim; Chan Soo Shin; Seong Yeon Kim Journal: Endocrinol Metab (Seoul) Date: 2020-09-22